Zeria Pharmaceutical Co., Ltd.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Zeria Pharmaceutical Co., Ltd. owes ¥0.40 for every ¥1 it owns. Net profit fell 15% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
10.6Investors pay ¥10.6 for every ¥1 of Zeria Pharmaceutical Co., Ltd.'s yearly profit, lower than 82% of Healthcare companies in Japan.
P/B ratio
0.81The share price is 0.81 times Zeria Pharmaceutical Co., Ltd.'s book value per share, lower than 86% of Healthcare companies in Japan.
Market cap
¥87.3 BThe total market value of all of Zeria Pharmaceutical Co., Ltd.'s shares at today's price (share price × number of shares), larger than 73% of Healthcare companies in Japan. PosiCap size class: Mini Cap.
Net worth (book value)
¥108.4 BWhat Zeria Pharmaceutical Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
¥2,459Net worth divided by the number of shares. The share price of ¥1,981 is 0.8 times this, which is the P/B above.
Return on equity (ROE)
8.4%Zeria Pharmaceutical Co., Ltd. earned 8.4% on its shareholders' money over the last year, higher than 56% of Healthcare companies in Japan.
Owes vs Owns
0.40×Zeria Pharmaceutical Co., Ltd. owes ¥0.40 for every ¥1 it owns (low).
Dividend yield
2.46%Zeria Pharmaceutical Co., Ltd. pays 2.46% of its share price as dividends a year, lower than 58% of dividend-paying Healthcare companies in Japan.
Revenue growth
+2%Revenue rose 2% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Profit growth
-15%Net profit fell 15% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Profit margin
9.5%Zeria Pharmaceutical Co., Ltd. keeps ¥9 of every ¥100 of revenue as net profit.
Cash quality
1.2×Cash from Zeria Pharmaceutical Co., Ltd.'s business was 1.2× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
24.7×Zeria Pharmaceutical Co., Ltd.'s operating profit covered its interest costs 24.7 times in the year to Mar 2026.
Cash vs debt
Net debtZeria Pharmaceutical Co., Ltd. had ¥11.3 B more debt than cash (net debt) at Mar 2026.
Questions
What is Zeria Pharmaceutical Co., Ltd.'s P/E ratio?
Investors pay ¥10.6 for every ¥1 of Zeria Pharmaceutical Co., Ltd.'s yearly profit, lower than 82% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Zeria Pharmaceutical Co., Ltd.: ¥87.3 B ÷ ¥108.4 B (31 Mar 2026) = 0.8.
What is Zeria Pharmaceutical Co., Ltd.'s return on equity?
Zeria Pharmaceutical Co., Ltd. earned 8.4% on its shareholders' money over the last year, higher than 56% of Healthcare companies in Japan.
How much does Zeria Pharmaceutical Co., Ltd. owe compared with what it owns?
Zeria Pharmaceutical Co., Ltd. owes ¥0.40 for every ¥1 it owns (low).
Does Zeria Pharmaceutical Co., Ltd. pay a dividend?
Yes. Zeria Pharmaceutical Co., Ltd. pays 2.46% of its share price as dividends a year, lower than 58% of dividend-paying Healthcare companies in Japan.
Is Zeria Pharmaceutical Co., Ltd.'s revenue growing?
Revenue rose 2% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.